iRadimed (NASDAQ:IRMD) Issues Q4 2025 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its fourth quarter 2025 earnings guidance on Monday morning. The company provided EPS guidance of 0.470-0.510 for the period, compared to the consensus EPS estimate of 0.470. The company issued revenue guidance of $21.4 million-$22.4 million, compared to the consensus revenue estimate of $20.7 million. iRadimed also updated its FY 2025 guidance to 1.840-1.880 EPS.

iRadimed Price Performance

iRadimed stock opened at $76.81 on Monday. The firm has a 50 day simple moving average of $73.14 and a 200-day simple moving average of $63.84. iRadimed has a 1-year low of $46.86 and a 1-year high of $80.64. The stock has a market cap of $976.64 million, a price-to-earnings ratio of 47.41 and a beta of 1.02.

Analyst Ratings Changes

IRMD has been the topic of several analyst reports. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of iRadimed in a report on Friday. Finally, Roth Capital set a $90.00 target price on shares of iRadimed in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating and two have issued a Buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $81.00.

Insider Buying and Selling

In related news, Director Monty K. Allen sold 1,102 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $69.10, for a total value of $76,148.20. Following the completion of the sale, the director directly owned 19,898 shares in the company, valued at approximately $1,374,951.80. The trade was a 5.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $77.69, for a total transaction of $388,450.00. Following the completion of the sale, the chief executive officer owned 2,327,500 shares of the company’s stock, valued at approximately $180,823,475. The trade was a 0.21% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 36,102 shares of company stock valued at $2,623,848. Company insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

Institutional investors and hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. boosted its position in shares of iRadimed by 766.6% during the 2nd quarter. Osaic Holdings Inc. now owns 3,813 shares of the medical equipment provider’s stock valued at $228,000 after purchasing an additional 3,373 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. Lazard Asset Management LLC lifted its stake in iRadimed by 5.2% during the second quarter. Lazard Asset Management LLC now owns 41,110 shares of the medical equipment provider’s stock valued at $2,457,000 after buying an additional 2,036 shares in the last quarter. Brevan Howard Capital Management LP purchased a new stake in iRadimed during the second quarter valued at about $260,000. Finally, Jane Street Group LLC lifted its stake in iRadimed by 30.5% during the second quarter. Jane Street Group LLC now owns 9,183 shares of the medical equipment provider’s stock valued at $549,000 after buying an additional 2,145 shares in the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

About iRadimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.